SA leg of MMR trial to protect healthcare workers against Sars-CoV-2

Organisation: Position: Deadline Date: Location:

Researchers are preparing to launch the South Africa leg of an international trial investigating whether the well-established measles, mumps and rubella (MMR) shot used in childhood immunisation programmes can protect front-line health-care workers from Sars-CoV-2, the virus that causes COVID-19, reports Business Day.

The trial is co-led by Wits University, Washington University and University College London, through the COVID-19 Research Outcomes Worldwide Network for Coronavirus Prevention (Crown Coronation) collaborative. It is funded by a $9m grant from the Covid-19 Tools ACT accelerator, a global collaboration backed by the Bill & Melinda Gates Foundation, with a R1m contribution from the SA Medical Research Council for the local aspect of the study.

The report says the trial aims to recruit 30,000 health-care workers in the US, UK, Canada, Ireland, Netherlands, Ghana, Uganda, South Africa, Zambia and Zimbabwe. Health-care workers face continued exposure to COVID-19 even in regions where the epidemic is declining, such as South Africa.

“COVID-19 has not gone away. We are waiting to see if there will be a second wave,” co-principal investigator Sinead Delany-Moretlwe, research director at the Wits Reproductive Health and HIV Institute is quoted in Business Day as saying.

 

Full Business Day report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.